TACSTD2 and triple-negative breast carcinoma: Preclinical results, supported by an ongoing clinical trial, highlight the attributes distinguishing this anti-Trop-2-targeting ADC as a novel agent for the treatment of patients with relapsed/refractory, metastatic solid cancers [24], especially triple-negative breast cancer (TNBC) [25].